{
    "organizations": [],
    "uuid": "ffebafbad60ff108ab442d1e67a55b61447bbfd6",
    "author": "",
    "url": "https://www.reuters.com/article/brief-karyopharm-therapeutics-reports-q4/brief-karyopharm-therapeutics-reports-q4-loss-per-share-of-0-80-idUSASC09SDX",
    "ord_in_thread": 0,
    "title": "BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 15, 2018 / 11:20 AM / Updated 5 minutes ago BRIEF-Karyopharm Therapeutics Reports Q4 Loss Per Share Of $0.80 Reuters Staff March 15 (Reuters) - Karyopharm Therapeutics Inc: * KARYOPHARM REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS * Q4 LOSS PER SHARE $0.80 * Q4 EARNINGS PER SHARE VIEW $-0.65 â€” THOMSON REUTERS I/B/E/S * PHASE 2B STORM STUDY EVALUATING SELINEXOR IN PATIENTS WITH PENTA-REFRACTORY MYELOMA REMAINS ON TRACK * TOP-LINE DATA FROM PHASE 2B STORM STUDY EXPECTED END OF APRIL 2018 * KARYOPHARM - CASH, CASH EQUIVALENTS AND INVESTMENTS AS OF DEC 31, 2017, INCLUDING RESTRICTED CASH, TOTALED $176.4 MILLION, VERSUS $175.5 MILLION AT DEC 31, 2016 * EXPECTS EXISTING CASH, CASH EQUIVALENTS AND INVESTMENTS TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q1 2019 * QTRLY LICENSE AND OTHER REVENUE $1.5 MILLION VERSUS $ 47,000 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-03-15T13:18:00.000+02:00",
    "crawled": "2018-03-15T13:38:51.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "report",
        "q4",
        "loss",
        "per",
        "share",
        "reuters",
        "staff",
        "march",
        "reuters",
        "karyopharm",
        "therapeutic",
        "inc",
        "karyopharm",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "highlight",
        "recent",
        "progress",
        "q4",
        "loss",
        "per",
        "share",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "phase",
        "2b",
        "storm",
        "study",
        "evaluating",
        "selinexor",
        "patient",
        "myeloma",
        "remains",
        "track",
        "data",
        "phase",
        "2b",
        "storm",
        "study",
        "expected",
        "end",
        "april",
        "karyopharm",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "dec",
        "including",
        "restricted",
        "cash",
        "totaled",
        "million",
        "versus",
        "million",
        "dec",
        "expects",
        "existing",
        "cash",
        "cash",
        "equivalent",
        "investment",
        "sufficient",
        "fund",
        "operation",
        "least",
        "q1",
        "qtrly",
        "license",
        "revenue",
        "million",
        "versus",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}